Oncotarget

Research Papers:

Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells

Wen Zhang, Li Bao, Shaoxing Yang, Zhaoyang Qian, Mei Dong, Liyuan Yin, Qian Zhao, Keli Ge, Zhenling Deng, Jing Zhang, Fei Qi, Zhongxue An, Yuan Yu, Qingbo Wang, Renhua Wu, Fan Fan, Lianfeng Zhang, Xiping Chen, Yingjian Na, Lin Feng, Lingling liu, Yujie Zhu, Tiancheng Qin, Shuren Zhang, Youhui Zhang, Xiuqing Zhang, Jian Wang, Xin Yi, Liqun Zou, Hong-Wu Xin, Henrik J. Ditzel, Hongjun Gao, Kaitai Zhang, Binlei Liu _ and Shujun Cheng

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:39768-39783. https://doi.org/10.18632/oncotarget.9465

Metrics: PDF 2024 views  |   HTML 1228 views  |   ?  


Abstract

Wen Zhang1,*, Li Bao3,9,10,*, Shaoxing Yang6,*, Zhaoyang Qian3,*, Mei Dong4,*, Liyuan Yin2,19, Qian Zhao7, Keli Ge1, Zhenling Deng1, Jing Zhang5, Fei Qi8, Zhongxue An3, Yuan Yu3, Qingbo Wang3, Renhua Wu3, Fan Fan3, Lianfeng Zhang16, Xiping Chen17, Yingjian Na17, Lin Feng2, Lingling liu1, Yujie Zhu1, Tiancheng Qin2, Shuren Zhang1, Youhui Zhang1, Xiuqing Zhang3,11,12, Jian Wang3,13, Xin Yi3, Liqun Zou5, Hong-Wu Xin18, Henrik J. Ditzel10,14, Hongjun Gao6, Kaitai Zhang2, Binlei Liu15,1, Shujun Cheng2

1Department of Immunology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

2State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

3BGI-Shenzhen, Shenzhen 518083, China

4Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

5Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China

6Department of Pulmonary Oncology, Affiliated Hospital, Academy of Military Medical Science, Beijing 100071, China

7Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

8Department of Respiratory Diseases, Chinese PLA General Hospital, Beijing 100853, China

9Molecular Disease Biology Section, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Danish Cancer Society, DK-2100 Copenhagen, Denmark

10Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense C, Denmark

11The Guangdong Enterprise Key Laboratory of Human Disease Genomics, BGI-Shenzhen, Shenzhen 518083, China

12Shenzhen Key Laboratory of Transomics Biotechnologies, BGI-Shenzhen, 518083 Shenzhen, China

13James D. Watson Institute of Genome Science, 310008 Hangzhou, China

14Department of Oncology, Odense University Hospital, DK-5000 Odense C, Denmark

15Hubei Provincial Cooperative, Innovation Center of Industrial Fermentation, Hubei University of Technology, Wuhan 30068, China

16Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 10021, China

17Institute of Environmental Health and Related Product Safety, China CDC, Beijing 10021, China

18Laborartory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing 100142, China

19Lung Cancer Center, Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China

*These authors contributed equally to this work

Correspondence to:

Binlei Liu, email: liubinlei@cicams.ac.cn

Kaitai Zhang, email: zhangkt@cicams.ac.cn

Hongjun Gao, email: gaohj6708@hotmail.com

Keywords: viable circulating tumor cells, epithelial-marker-independent, telomerase-specific HSV, clinical application

Received: October 20, 2015     Accepted: April 24, 2016     Published: May 18, 2016

ABSTRACT

Detection of circulating tumor cells remains a significant challenge due to their vast physical and biological heterogeneity. We developed a cell-surface-marker-independent technology based on telomerase-specific, replication-selective oncolytic herpes-simplex-virus-1 that targets telomerase-reverse-transcriptase-positive cancer cells and expresses green-fluorescent-protein that identifies viable CTCs from a broad spectrum of malignancies. Our method recovered 75.5–87.2% of tumor cells spiked into healthy donor blood, as validated by different methods, including single cell sequencing. CTCs were detected in 59–100% of 326 blood samples from patients with 6 different solid organ carcinomas and lymphomas. Significantly, CTC-positive rates increased remarkably with tumor progression from N0M0, N+M0 to M1 in each of 5 tested cancers (lung, colon, liver, gastric and pancreatic cancer, and glioma). Among 21 non-small cell lung cancer cases in which CTC values were consecutively monitored, 81% showed treatment-related decreases, which was also found after treatments in the other solid tumors. Moreover, monitoring CTC values provided an efficient treatment response indicator in hematological malignancies. Compared to CellSearch, our method detected significantly higher positive rates in 40 NSCLC in all stages, including N0M0, N+M0 and M1, and was less affected by chemotherapy. This simple, robust and clinically-applicable technology detects viable CTCs from solid and hematopoietic malignancies in early to late stages, and significantly improves clinical detection and treatment prognostication.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9465